1746 related articles for article (PubMed ID: 16938815)
1. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
4. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
Kassim I; Dirkx ML; Heijmen BJ
Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
[TBL] [Abstract][Full Text] [Related]
7. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
[TBL] [Abstract][Full Text] [Related]
8. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
9. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
Muren LP; Wasbø E; Helle SI; Hysing LB; Karlsdottir A; Odland OH; Valen H; Ekerold R; Johannessen DC
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1034-41. PubMed ID: 18249502
[TBL] [Abstract][Full Text] [Related]
11. Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: a radiation treatment planner's perspective.
Parker W; Patrocinio H
Can J Urol; 2005 Jun; 12 Suppl 2():48-52. PubMed ID: 16018834
[TBL] [Abstract][Full Text] [Related]
12. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
Ganswindt U; Paulsen F; Corvin S; Hundt I; Alber M; Frey B; Stenzl A; Bares R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):347-55. PubMed ID: 17236960
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
[TBL] [Abstract][Full Text] [Related]
14. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V
Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377
[TBL] [Abstract][Full Text] [Related]
15. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk.
Ahmed RS; Kim RY; Duan J; Meleth S; De Los Santos JF; Fiveash JB
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):505-12. PubMed ID: 15380585
[TBL] [Abstract][Full Text] [Related]
16. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.
Fiorino C; Alongi F; Perna L; Broggi S; Cattaneo GM; Cozzarini C; Di Muzio N; Fazio F; Calandrino R
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):29-35. PubMed ID: 19467803
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
[TBL] [Abstract][Full Text] [Related]
18. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
19. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
